Showing results (61-70 of 77) with videos related to
Sort By:
Pageof 8
JHEP Reports : Innovation in Hepatology|April 28, 2025
Metabolomic liquid biopsy dynamics predict early-stage HCC and actionable candidates of human hepatocarcinogenesisKornelius Schulze, Tim Daniel Rose, Lorenz Adlung, et al.Hepatology International|April 3, 2023
Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinomaMathew Vithayathil, Antonio D'Alessio, Claudia Angela Maria Fulgenzi, et al.Cancers|December 11, 2022
Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus BevacizumabYue Linda Wu, Claudia Angela Maria Fulgenzi, Antonio D'Alessio, et al.Hepatology (Baltimore, Md.)|March 21, 2022
Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world studyAntonio D'Alessio, Claudia Angela Maria Fulgenzi, Naoshi Nishida, et al.Hepatology Communications|October 27, 2023
Efficacy and safety of atezolizumab/bevacizumab in patients with HCC after prior systemic therapy: A global, observational studyVincent Joerg, Bernhard Scheiner, Antonio D Alessio, et al.Hepatology Communications|November 4, 2024
Atezolizumab/bevacizumab and lenvatinib for hepatocellular carcinoma: A comparative analysis in a European real-world cohortTiago de Castro, Sabrina Welland, Leonie Jochheim, et al.European Journal of Cancer (Oxford, England : 1990)|September 23, 2022
Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real studyClaudia Angela Maria Fulgenzi, Jaekyung Cheon, Antonio D'Alessio, et al.Journal of Hepatology|October 14, 2021
Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY scoreBernhard Scheiner, Katharina Pomej, Martha M Kirstein, et al.Journal of Hepatocellular Carcinoma|April 9, 2025
ALBI Grade Enables Risk Stratification for Bleeding Events and Refines Prognostic Prediction in Advanced HCC Following Atezolizumab and BevacizumabBernardo Stefanini, Claudia Angela Maria Fulgenzi, Bernhard Scheiner, et al.Hepatology (Baltimore, Md.)|October 21, 2019
Genetic Variation in HSD17B13 Reduces the Risk of Developing Cirrhosis and Hepatocellular Carcinoma in Alcohol MisusersFelix Stickel, Philipp Lutz, Stephan Buch, et al.Pageof 8